Quick Answer
Altamira Therapeutics Ltd. reported R&D Expense of $3.73 million for fiscal year 2024.
Altamira Therapeutics Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $3.73M | +10.3% |
| 2023 | $3.38M | -77.9% |
| 2022 | $15.31M | +378.1% |
| 2021 | $3.20M | +11.9% |
| 2020 | $2.86M | -13.9% |
| 2019 | $3.33M | -50.3% |
| 2018 | $6.69M | -65.2% |
| 2017 | $19.21M | -22.5% |
| 2016 | $24.78M | -6.6% |
| 2015 | $26.54M | — |
- Altamira Therapeutics Ltd. showed an increase of +10.3% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2024 period, Altamira Therapeutics Ltd.’s r&d expense has declined by 86.0% (from $26.54 million to $3.73 million).
- The most recent figure is from Altamira Therapeutics Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: